Acquired Bleeding Disorder

0

Pipeline Programs

1

Companies

25

Clinical Trials

0

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

0

0

0

0

0

0

0

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1

P1/2

P2

P2/3

P3

Mkt

Novo NordiskBAGSVAERD DENMARK, Denmark

25 programs

activated recombinant human factor VIIN/A1 trial

activated recombinant human factor VIIN/A1 trial

activated recombinant human factor VIIPHASE_11 trial

catridecacogPHASE_11 trial

catridecacogPHASE_11 trial

+20 more programs

Active Trials

NCT01285089Completed21Est. Oct 2013

NCT00124293Completed63Est. Nov 2005

NCT01561417Completed28Est. Sep 2006

+22 more trials

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Novo Nordiskactivated recombinant human factor VII

Novo Nordiskeptacog alfa

Novo Nordiskeptacog alfa

Novo Nordiskactivated recombinant human factor VII

Novo Nordiskcatridecacog

Novo Nordiskeptacog alfa

Novo Nordiskactivated recombinant human factor VII

Novo Nordiskactivated recombinant human factor VII

Novo Nordiskeptacog alfa

Novo Nordiskactivated recombinant human factor VII

Novo Nordiskactivated recombinant human factor VII

Novo Nordiskactivated recombinant human factor VII

Novo Nordiskstandard therapy

Novo Nordiskactivated recombinant human factor VII

Novo Nordiskactivated recombinant human factor VII

Showing 15 of 25 trials with date data

Clinical Trials (25)

Total enrollment: 4,197 patients across 25 trials

NCT00323570 Novo Nordiskactivated recombinant human factor VII

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

Start: May 2006Est. completion: Jun 20070

Phase 3Withdrawn

NCT00184548 Novo Nordiskeptacog alfa

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

Start: Oct 2005Est. completion: Sep 2008554 patients

Phase 3Terminated

NCT00127283 Novo Nordiskeptacog alfa

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Start: May 2005Est. completion: Jan 2007829 patients

Phase 3Completed

NCT01562574 Novo Nordiskactivated recombinant human factor VII

Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease

Start: Jan 2002Est. completion: Aug 200482 patients

Phase 3Completed

NCT00914589 Novo Nordiskcatridecacog

Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

Start: Jul 2009Est. completion: Feb 2011479 patients

Phase 2Completed

NCT00266006 Novo Nordiskeptacog alfa

Factor VIIa in Acute Intracerebral Haemorrhage

Start: Jan 2006Est. completion: Apr 200790 patients

Phase 2Completed

NCT00123591 Novo Nordiskactivated recombinant human factor VII

Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury

Start: Jan 2005Est. completion: May 200696 patients

Phase 2Completed

NCT00154427 Novo Nordiskactivated recombinant human factor VII

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

Start: Aug 2004Est. completion: Nov 2007172 patients

Phase 2Terminated

NCT00102037 Novo Nordiskeptacog alfa

Use of Activated Recombinant FVII in Spinal Surgery

Start: Jul 2004Est. completion: Feb 200650 patients

Phase 2Completed

NCT00154492 Novo Nordiskactivated recombinant human factor VII

Use of NovoSeven® in Active Variceal Bleeding

Start: Apr 2004Est. completion: Aug 2006265 patients

Phase 2Completed

NCT01601457 Novo Nordiskactivated recombinant human factor VII

Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction

Start: Sep 2002Est. completion: Apr 200448 patients

Phase 2Completed

NCT00426803 Novo Nordiskactivated recombinant human factor VII

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Start: Aug 2002Est. completion: Jun 2004400 patients

Phase 2Completed

NCT01564563 Novo Nordiskstandard therapy

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Start: Jun 2002Est. completion: Oct 200311 patients

Phase 2Terminated

NCT01563523 Novo Nordiskactivated recombinant human factor VII

Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients

Start: Mar 2002Est. completion: Oct 2003283 patients

Phase 2Completed

NCT01563445 Novo Nordiskactivated recombinant human factor VII

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Start: Nov 2001Est. completion: Mar 200340 patients

Phase 2Completed

NCT01566786 Novo Nordiskactivated recombinant human factor VII

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage

Start: Aug 2001Est. completion: Oct 200248 patients

Phase 2Completed

NCT01563458 Novo Nordiskactivated recombinant human factor VII

Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation

Start: Aug 2001Est. completion: Aug 2003208 patients

Phase 2Completed

NCT01562821 Novo Nordiskactivated recombinant human factor VII

Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

Start: Jul 2001Est. completion: Dec 2002235 patients

Phase 2Completed

NCT01601613 Novo Nordiskactivated recombinant human factor VII

Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

Start: Jul 2001Est. completion: Nov 200228 patients

Phase 2Completed

NCT01562158 Novo Nordiskstandard therapy

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Start: Apr 2001Est. completion: Oct 2003100 patients

Phase 2Completed

NCT01153997 Novo Nordiskcatridecacog

Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers

Start: Jun 2010Est. completion: Aug 201024 patients

Phase 1Completed

NCT01561417 Novo Nordiskactivated recombinant human factor VII

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Start: Apr 2006Est. completion: Sep 200628 patients

Phase 1Completed

NCT02239146 Novo Nordiskcatridecacog

Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass

Start: Oct 2005Est. completion: Jan 200843 patients

Phase 1Completed

NCT01285089 Novo Nordiskactivated recombinant human factor VII

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

Start: Dec 2010Est. completion: Oct 201321 patients

N/ACompleted

NCT00124293 Novo Nordiskactivated recombinant human factor VII

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Start: Oct 2004Est. completion: Nov 200563 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.